FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1970784908> ?p ?o ?g. }

• W1970784908 endingPage "1537" @default.
• W1970784908 startingPage "1529" @default.
• W1970784908 abstract "Introduction:This randomized open-label phase II study evaluated the efficacy, safety, and tolerability of pazopanib in combination with pemetrexed compared with the standard cisplatin/pemetrexed doublet in patients with previously untreated, advanced, nonsquamous non–small-cell lung cancer.Methods:Patients were randomized (2:1 ratio) to receive pemetrexed 500 mg/m2 intravenously once every 3 weeks plus either oral pazopanib 800 mg daily or cisplatin 75 mg/m2 intravenously once every 3 weeks up to six cycles. All patients received folic acid, vitamin B12, and steroid prophylaxis. The primary endpoint was progression-free survival (PFS).Results:The study was terminated after 106 of 150 patients were randomized due to a higher incidence of adverse events leading to withdrawal from the study and severe and fatal adverse events in the pazopanib/pemetrexed arm than in the cisplatin/pemetrexed arm. At the time enrolment was discontinued, there were three fatal adverse events in the pazopanib/pemetrexed arm, including ileus, tumor embolism, and bronchopneumonia/sepsis. Treatment with pazopanib/pemetrexed was discontinued resulting in more PFS data censored for patients in the pazopanib/pemetrexed arm than those in the cisplatin/pemetrexed arm. There was no statistically significant difference between the pazopanib/pemetrexed and cisplatin/pemetrexed arms for PFS (median PFS, 25.0 versus 22.9 weeks, respectively; hazard ratio = 0.75; 95% confidence interval, 0.43%–1.28%; p = 0.26) or objective response rate (23% versus 34%, respectively; 95% confidence interval, –30.6% to 7.2%; p = 0.21).Conclusion:The combination of pazopanib/pemetrexed in first-line treatment of non–small-cell lung cancer showed some antitumor activity but had unacceptable levels of toxicity." @default.
• W1970784908 created "2016-06-24" @default.
• W1970784908 creator A5023794502 @default.
• W1970784908 creator A5025376682 @default.
• W1970784908 creator A5026119562 @default.
• W1970784908 creator A5027374550 @default.
• W1970784908 creator A5027768129 @default.
• W1970784908 creator A5029244284 @default.
• W1970784908 creator A5029761367 @default.
• W1970784908 creator A5029862849 @default.
• W1970784908 creator A5036858464 @default.
• W1970784908 creator A5049829108 @default.
• W1970784908 creator A5055798090 @default.
• W1970784908 creator A5060572768 @default.
• W1970784908 creator A5061268044 @default.
• W1970784908 creator A5079802303 @default.
• W1970784908 date "2013-12-01" @default.
• W1970784908 modified "2023-09-26" @default.
• W1970784908 title "An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non–Small-Cell Lung Cancer" @default.
• W1970784908 cites W1977591797 @default.
• W1970784908 cites W2005244154 @default.
• W1970784908 cites W2020159902 @default.
• W1970784908 cites W2052335855 @default.
• W1970784908 cites W2053519484 @default.
• W1970784908 cites W2073979951 @default.
• W1970784908 cites W2074190059 @default.
• W1970784908 cites W2099725888 @default.
• W1970784908 cites W2102627969 @default.
• W1970784908 cites W2109240520 @default.
• W1970784908 cites W2112621029 @default.
• W1970784908 cites W2124776048 @default.
• W1970784908 cites W2125357549 @default.
• W1970784908 cites W2127809030 @default.
• W1970784908 cites W2129793485 @default.
• W1970784908 cites W2133232813 @default.
• W1970784908 cites W2134667653 @default.
• W1970784908 cites W2139248078 @default.
• W1970784908 cites W2144660856 @default.
• W1970784908 cites W2145653040 @default.
• W1970784908 cites W2145835533 @default.
• W1970784908 cites W2150358925 @default.
• W1970784908 cites W2155236705 @default.
• W1970784908 cites W2156800473 @default.
• W1970784908 cites W2159370421 @default.
• W1970784908 cites W2162424705 @default.
• W1970784908 cites W2170024262 @default.
• W1970784908 cites W2178828310 @default.
• W1970784908 cites W2226490553 @default.
• W1970784908 cites W2319650146 @default.
• W1970784908 cites W2565534798 @default.
• W1970784908 cites W2588933585 @default.
• W1970784908 cites W2603225534 @default.
• W1970784908 cites W4235930443 @default.
• W1970784908 cites W4237364964 @default.
• W1970784908 doi "https://doi.org/10.1097/jto.0000000000000005" @default.
• W1970784908 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24389434" @default.
• W1970784908 hasPublicationYear "2013" @default.
• W1970784908 type Work @default.
• W1970784908 sameAs 1970784908 @default.
• W1970784908 citedByCount "32" @default.
• W1970784908 countsByYear W19707849082014 @default.
• W1970784908 countsByYear W19707849082015 @default.
• W1970784908 countsByYear W19707849082016 @default.
• W1970784908 countsByYear W19707849082017 @default.
• W1970784908 countsByYear W19707849082018 @default.
• W1970784908 countsByYear W19707849082019 @default.
• W1970784908 countsByYear W19707849082021 @default.
• W1970784908 crossrefType "journal-article" @default.
• W1970784908 hasAuthorship W1970784908A5023794502 @default.
• W1970784908 hasAuthorship W1970784908A5025376682 @default.
• W1970784908 hasAuthorship W1970784908A5026119562 @default.
• W1970784908 hasAuthorship W1970784908A5027374550 @default.
• W1970784908 hasAuthorship W1970784908A5027768129 @default.
• W1970784908 hasAuthorship W1970784908A5029244284 @default.
• W1970784908 hasAuthorship W1970784908A5029761367 @default.
• W1970784908 hasAuthorship W1970784908A5029862849 @default.
• W1970784908 hasAuthorship W1970784908A5036858464 @default.
• W1970784908 hasAuthorship W1970784908A5049829108 @default.
• W1970784908 hasAuthorship W1970784908A5055798090 @default.
• W1970784908 hasAuthorship W1970784908A5060572768 @default.
• W1970784908 hasAuthorship W1970784908A5061268044 @default.
• W1970784908 hasAuthorship W1970784908A5079802303 @default.
• W1970784908 hasBestOaLocation W19707849081 @default.
• W1970784908 hasConcept C121608353 @default.
• W1970784908 hasConcept C126322002 @default.
• W1970784908 hasConcept C143998085 @default.
• W1970784908 hasConcept C197934379 @default.
• W1970784908 hasConcept C207103383 @default.
• W1970784908 hasConcept C2776256026 @default.
• W1970784908 hasConcept C2776694085 @default.
• W1970784908 hasConcept C2777063308 @default.
• W1970784908 hasConcept C2777240266 @default.
• W1970784908 hasConcept C2778239845 @default.
• W1970784908 hasConcept C2778375690 @default.
• W1970784908 hasConcept C2778439243 @default.
• W1970784908 hasConcept C2779490328 @default.
• W1970784908 hasConcept C44249647 @default.
• W1970784908 hasConcept C71924100 @default.

• next